-17%
Description
GIP/GLP-1/Glucagon receptor agonist (triple incretin). Half-life approximately 5-7 days, subcutaneous injection typically once weekly.
Effect:
- Severe appetite suppression and weight loss
- Improved insulin sensitivity and fat metabolism
- Increased energy consumption due to glucagon activity
- Slowed gastric emptying
Dosage:
- Starting dose: 2mg/week (titration over 4-8 weeks)
- Maintenance: 4-8mg/week
- Maximum: up to 12mg/week
Additional information
| Active Ingredient | Retatrutide |
|---|---|
| Package size | 10IU |
Related products
-15%
-14%
